Pulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 5,779 Shares

Pulmonx Co. (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 5,779 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.13, for a total value of $41,204.27. Following the transaction, the insider now owns 285,278 shares of the company’s stock, valued at approximately $2,034,032.14. The trade was a 1.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Pulmonx Price Performance

Shares of NASDAQ LUNG traded down $0.48 during mid-day trading on Wednesday, reaching $8.19. The company had a trading volume of 240,321 shares, compared to its average volume of 337,083. Pulmonx Co. has a one year low of $5.46 and a one year high of $10.01. The firm has a market cap of $325.93 million, a price-to-earnings ratio of -5.69 and a beta of 0.64. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The business’s 50-day simple moving average is $6.89 and its 200 day simple moving average is $6.92.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. On average, research analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pulmonx

Large investors have recently modified their holdings of the company. Deerfield Management Company L.P. Series C bought a new stake in Pulmonx in the 4th quarter worth about $10,421,000. FMR LLC grew its stake in shares of Pulmonx by 11.2% during the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock worth $48,686,000 after acquiring an additional 591,859 shares during the period. PFM Health Sciences LP purchased a new stake in Pulmonx in the 3rd quarter worth about $3,058,000. Altium Capital Management LLC grew its position in shares of Pulmonx by 63.0% in the fourth quarter. Altium Capital Management LLC now owns 815,000 shares of the company’s stock valued at $5,534,000 after purchasing an additional 315,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in shares of Pulmonx during the third quarter valued at about $1,711,000. 91.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LUNG. Citigroup reissued a “neutral” rating and set a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Wells Fargo & Company cut their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.